Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.61), $0.11 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $57.4 million versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.